The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry neuropathy
Abstract
BACKGROUND: Peripheral neuropathy in Fabry disease predominantly involves small nerve fibers. Recently, enzyme replacement therapy (ERT) with recombinant human alpha-galactosidase A has become available. OBJECTIVE: To evaluate whether ERT improves Fabry neuropathy. METHODS: In 22 Fabry patients (age 27.9 +/- 8.0 years) undergoing ERT with recombinant human alpha-galactosidase A (agalsidase beta) for 18 (n = 11) or 23 (n = 11) months and in 25 control subjects (age 29.0 +/- 10.4 years), the authors performed quantitative sensory testing using the 4, 2, and 1 stepping algorithm (CASE IV). Detection thresholds of vibration (VDT) on the first toe were assessed; cold detection thresholds (CDT), heat-pain onset (HP 0.5), and intermediate heat-pain (HP 5.0) assessments were made on the dorsum of the feet. Patient values above mean + 2.5 SD of control values were considered abnormal. RESULTS: Before ERT, VDT, CDT, HP 0.5, and HP 5.0 were higher in patients than control subjects (p < 0.05). Following ERT, patients developed lower thresholds than prior to ERT for VDT (15.5 +/- 3.5 vs 14.3 +/- 4.1; p < 0.05), HP 0.5 (22.3 +/- 6.7 vs 19.4 +/- 1.3; p < 0.01), and HP 5.0 (27.3 +/- 5.6 vs 22.5 +/- 2.3; p < 0.01). Moreover, fewer patients had abnormal results of VDT (2 vs 4), CDT (7 vs 12), HP 0.5 (0 vs 9), and HP 5.0 (4 vs 20) after than before ERT. CONCLUSIONS: ERT therapy with agalsidase beta significantly improves function of C-, Adelta-, and Abeta-nerve fibers and intradermal vibration receptors in Fabry neuropathy. Lack of recovery in some patients with abnormal cold or heat-pain perception suggests the need for early ERT, prior to irreversible nerve fiber loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ziegler, D., Hanefeld, M., Ruhnau, K. J., Mei\ner, H. P., Lobisch, M., Sch�tte, K., Gries, F. A., & The ALADIN Study Group (1995) · Diabetologia · doi:10.1007/bf00400603 · Cited by 525
Cited by
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial
Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., Finkel, R., Packman, S., Bichet, D. G., Warnock, D. G., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00148 · Cited by 569
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
Wilcox, W. R., Oliveira, J. P., Hopkin, R. J., Ortiz, A., Banikazemi, M., Feldt-Rasmussen, U., Sims, K., Waldek, S., Pastores, G. M., Lee, P., et al. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.09.013 · Cited by 544
Influence of aging on thermal and vibratory thresholds of quantitative sensory testing
Lin, Y., Hsieh, S., Chao, C., Chang, Y., & Hsieh, S. (2005) · Journal of the Peripheral Nervous System · doi:10.1111/j.1085-9489.2005.10305.x · Cited by 176
A Systematic Review of Pharmacologic and Rehabilitative Treatment of Small Fiber Neuropathies
Vecchio, M., Chiaramonte, R., Romano, M., Pavone, P., Musumeci, G., & Mauro, G. L. (2020) · Diagnostics · doi:10.3390/diagnostics10121022 · Cited by 21
Metadata
- Authors
- Hilz, M. J., Brys, M., Marthol, H., Stemper, B., & Dütsch, M.
- Venue
- Neurology
- Published
- 2004-04-13
- Volume
- 62
- Issue
- 7
- Pages
- 1066-1072
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2090005375
- Cited by
- 170
- References
- 1
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry neuropathy. https://app.cochat.ai/papers/10.1212/01.wnl.0000118207.84514.40
- The paper
- Hilz, M. J., Brys, M., Marthol, H., Stemper, B., & Dütsch, M. (2004). Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry neuropathy. Neurology. https://doi.org/10.1212/01.wnl.0000118207.84514.40
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.